About Us

sphingotec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. Read More...

SPHINGOTEC GROUP

COMBINING INNOVATIVE BIOMARKER WITH OUTSTANDING TECHNOLOGY

 

LATEST NEWS

  • sphingotec is adding an advanced POC testing platform to portfolio

    sphingotec is adding an advanced POC testing platform to portfolio

  • Medical leaders support novel theranostic approach to help patients with leaky blood vessels

    Medical leaders support novel theranostic approach to help patients with leaky blood vessels

  • Ortho Clinical Diagnostics and sphingotec Announce Strategic Agreement Regarding Novel Biomarker for Decreasing Re-hospitalizations in Heart Failure

    Ortho Clinical Diagnostics and sphingotec Announce Strategic Agreement Regarding Novel Biomarker for Decreasing Re-hospitalizations in Heart Failure

  • sphingotec Announces Collaboration with Mayo Clinic for Evaluation and Use of Biomarkers

    sphingotec Announces Collaboration with Mayo Clinic for Evaluation and Use of Biomarkers

previous arrow
next arrow
Slider

 

BIOMARKER

Sphingotest penKid
sphingotest® penKid®
Sphingotest bio-ADM
sphingotest® bio-ADM®

 
 

OUR PARTNERS

 

Top